AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰 Latest breakthroughs
🗺️ Disease Atlas · Cancer or benign tumor

soft tissue sarcoma

A malignant neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.

🔔 Follow weekly
🧬6011genes / proteins with evidence
💊233drugs and clinical candidates
🧪12+recruiting trials worldwide
✅3approved
📈41phase 3
🧬

Understand soft tissue sarcoma

Cancer · Cells that grow out of control
🎓 Learn more

What it is

No one knows exactly what causes these cancers. They are not common, but you have a higher risk if you have been exposed to certain chemicals, have had radiation therapy, or have certain genetic diseases.

Doctors diagnose soft tissue sarcomas with a biopsy. Treatments include surgery to remove the tumor, radiation therapy, chemotherapy, or a combination.

NIH: National Cancer Institute

From MedlinePlus: Soft Tissue Sarcoma (US National Library of Medicine) ↗

🧬 Cancer: Cancer is a group of diseases in which some of the body's cells grow and divide without control, and can spread to other parts of the body.

❓ Why it happens

  • Changes (mutations) build up in the genes that tell a cell when to grow, divide and die.
  • Most of these changes happen during life: tobacco, too much sun, alcohol, some infections (such as HPV and hepatitis B and C), radiation, obesity and ageing all raise the risk.
  • Some people inherit a faulty gene that raises their risk, such as BRCA1 or BRCA2.

🫀 What it does to the body

  • Cancer cells form a lump (tumour) that can press on or invade nearby organs.
  • They can travel through the blood or lymph to start new tumours elsewhere (metastasis).
  • Blood cancers crowd out healthy blood cells in the bone marrow.

🧱 Why it is hard to cure

  • Every cancer is different, even between two people with the same type - and inside one tumour.
  • Cancer cells keep changing, so they can learn to resist a medicine that worked at first.
  • Cancer cells are the body's own cells, so killing them without harming healthy cells is hard.
  • Many cancers cause no symptoms until they have spread, and a new medicine often takes more than ten years to go from the lab to patients.

🚀 What research is trying now

  • Targeted medicines against the exact gene change in a tumour (for example EGFR, ALK or KRAS).
  • Immunotherapy that helps the immune system recognise cancer, including CAR-T cell therapy.
  • Personalised cancer vaccines built from each tumour's mutations, now in late trials.
  • Blood tests that look for tumour DNA to find cancer earlier, and AI to read scans and slides.

General information about cancer, reviewed by people; it does not describe any one person. Below: the evidence for soft tissue sarcoma itself.

🤖

AI briefing

Where the science on soft tissue sarcoma stands, from the evidence on this page

AI reads the targets, drugs, trials and papers below and writes where the science stands — every claim cited. It is shared with everyone who opens soft tissue sarcoma.

🎯

Top targets

Genes and proteins ranked by Open Targets evidence (0-1)
SMARCB1 SWI/SNF related BAF chromatin remodeling complex subunit B1PROTACsmall molecule🧊 AlphaFold structure ↗ 0.87
SMARCA4 SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4PROTACsmall molecule🧊 AlphaFold structure ↗ 0.84
NF1 neurofibromin 1PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.79
DICER1 dicer 1, ribonuclease IIIPROTAC🧊 AlphaFold structure ↗ 0.79
TP53 tumor protein p53PROTACothersmall molecule🧊 AlphaFold structure ↗ 0.77
PAX3 paired box 3🧊 AlphaFold structure ↗ 0.76
PDGFRB platelet derived growth factor receptor betaPROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.71
PAX7 paired box 7🧊 AlphaFold structure ↗ 0.70
KIT KIT proto-oncogene, receptor tyrosine kinasePROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.70
ATRX ATRX chromatin remodelerPROTAC🧊 AlphaFold structure ↗ 0.68
KDR kinase insert domain receptorPROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.68
FGFR4 fibroblast growth factor receptor 4PROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.68
SSX1 SSX family member 1PROTAC🧊 AlphaFold structure ↗ 0.68
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinasePROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.68
PDGFRA platelet derived growth factor receptor alphaPROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.67

Green labels: what the target is known to be druggable by. The score combines genetics, somatic mutations, drugs, expression and literature.

💊

Drugs and candidates

Every medicine linked to soft tissue sarcoma, by how far it has got
Approved · 3
OlaratumabPlatelet-derived growth factor receptor alpha antagonistApproved
Pazopanib HydrochlorideMacrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor…Approved
TrabectedinApproved
In phase 2 / 3 · 20
AldoxorubicinDNA topoisomerase II alpha inhibitorPhase 3
BrigimadlinPhase 3
CapmatinibHepatocyte growth factor receptor inhibitorPhase 3
CarboplatinPhase 3
Catequentinib HydrochloridePhase 3
CeritinibALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitorPhase 3
Show all 20
CyclophosphamidePhase 3
DabrafenibSerine/threonine-protein kinase B-raf inhibitorPhase 3
DacarbazinePhase 3
DactinomycinPhase 3
DexamethasoneGlucocorticoid receptor agonistPhase 3
DocetaxelTubulin inhibitorPhase 3
DoxorubicinDNA topoisomerase II alpha inhibitorPhase 3
Doxorubicin HydrochlorideDNA topoisomerase II alpha inhibitorPhase 3
DurvalumabProgrammed cell death 1 ligand 1 inhibitorPhase 3
EpirubicinPhase 3
Epirubicin HydrochloridePhase 3
EtoposideDNA topoisomerase II inhibitorPhase 3
EvofosfamidePhase 3
EzabenlimabPhase 3
Early trials · 20
AvelumabProgrammed cell death 1 ligand 1 otherPhase 1/2
BelinostatHistone deacetylase inhibitorPhase 1/2
BexmarilimabPhase 1/2
CobimetinibDual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mi…Phase 1/2
ConatumumabTumor necrosis factor receptor superfamily member 10B agonistPhase 1/2
ExlinkibartPhase 1/2
Show all 20
Lb-100Serine/threonine protein phosphatase 2A, catalytic subunit, alpha isoform inhibitor; Seri…Phase 1/2
LurbinectedinPhase 1/2
MethotrexateDihydrofolate reductase inhibitorPhase 1/2
NaxtarubicinPhase 1/2
PexidartinibMacrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor…Phase 1/2
PucotenlimabProgrammed cell death protein 1 inhibitorPhase 1/2
RetifanlimabProgrammed cell death protein 1 antagonistPhase 1/2
SiremadlinTumour suppressor p53/oncoprotein Mdm2 inhibitorPhase 1/2
Sra-737Phase 1/2
SunitinibMacrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor…Phase 1/2
Sunitinib MalateMacrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor…Phase 1/2
TroculeucelPhase 1/2
AdebrelimabProgrammed cell death 1 ligand 1 inhibitorPhase 1
Ar-42Phase 1
🧪

Recruiting trials

Worldwide, open to new patients now
Safety and Efficacy of Preoperative SBRT and Radical Surgery for Soft Tissue Sarcoma of ExtremitiesNCT06760221 · NA · 📍 HangzhouA Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, …NCT05735184 · Phase 1 · 📍 PhoenixA Study of MT-4561 in Patients With Various Advanced Solid TumorsNCT06943521 · Phase 1, Phase 2 · 📍 Los AngelesDisulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory SarcomasNCT05210374 · Phase 1 · 📍 ClevelandRare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordNCT01793168 · n/a · 📍 Sioux FallsAlpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and …NCT02508038 · Phase 1 · 📍 MadisonTesting Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM TrialNCT05333458 · Phase 2 · 📍 Los AngelesDFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or OsteosarcomaNCT06892678 · Phase 1, Phase 2 · 📍 The BronxExercise and Soft Tissue SarcomaNCT04921917 · NA · 📍 DurhamBrachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sar…NCT05894018 · Phase 2 · 📍 GuangzhouEvaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcom…NCT04751409 · Phase 2 · 📍 HoustonStudy of NY-ESO-1 TCR-T in Advanced Soft Tissue SarcomaNCT05620693 · NA · 📍 Shenzhen Search more trials →
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy